日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)

贝伐珠单抗联合每周一次阿奈妥单抗或每周一次紫杉醇治疗铂类耐药/难治性高级别卵巢癌的随机 II 期研究(NCI 试验)

Alqaisi, Husam A; Cohn, David E; Chern, Jing-Yi; Duska, Linda R; Jewell, Andrea; Corr, Bradley R; Winer, Ira Seth; Girda, Eugenia; Crispens, Marta A; Dhani, Neesha C; Madariaga, Ainhoa; Grant, Robert C; Malaguti, Matthew; Lee, Crystal; Bowering, Valerie; Wong, Horace; Poothullil, Andrew; Speers, Vanessa; Wang, Lisa; Bedard, Philippe L; Brady, John C; Nixon, Andrew B; Chen, Li; O'Connor, Claire; Zamboni, William; McKee, Tawyna; Moscow, Jeffrey A; Oza, Amit M; Lheureux, Stephanie

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

一项多中心 II 期临床试验的临床结果和生物标志物评估,评估尼拉帕尼联合或不联合多司他利单抗治疗复发性子宫内膜癌的效果

Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C Dhani, Waldo Jimenez, Stephen Welch, Helen MacKay, Josee-Lyne Ethier, Lucy Gilbert, Xuan Li, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tong Zhang, Ian King, Gregory Downs, Tracy Stockley, Lisa Wang, Smitha Udagani, Amit M Oz

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

在 EVOLVE 研究中,通过循环肿瘤 DNA 识别 PARP 抑制剂进展时卵巢癌的 Cediranib 联合 Olaparib 的耐药机制,这是一项 II 期试验。

Lheureux, Stephanie; Prokopec, Stephenie D; Oldfield, Leslie E; Gonzalez-Ochoa, Eduardo; Bruce, Jeffrey P; Wong, Derek; Danesh, Arnavaz; Torti, Dax; Torchia, Jonathan; Fortuna, Alexander; Singh, Sharanjit; Irving, Matthew; Marsh, Kayla; Lam, Bernard; Speers, Vanessa; Yosifova, Aleksandra; Oaknin, Ana; Madariaga, Ainhoa; Dhani, Neesha C; Bowering, Valerie; Oza, Amit M; Pugh, Trevor J

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer

快速变化的格局:免疫检查点抑制剂在预处理转移性子宫内膜癌中的应用

Tinker, Anna V; Dhani, Neesha C; Ghatage, Prafull; McLeod, Deanna; Samouëlian, Vanessa; Welch, Stephen A; Altman, Alon D

Prey availability and foraging activity by tundra-nesting sea ducks: Strong preference for specific wetland types

苔原筑巢海鸭的猎物可获得性和觅食活动:对特定湿地类型有强烈的偏好

Miller, Micah W C; Lovvorn, James R; Graff, Nathan R; Stellrecht, Neesha C; Plesh, Steven P

FBXW7-loss Sensitizes Cells to ATR Inhibition Through Induced Mitotic Catastrophe

FBXW7缺失通过诱导有丝分裂灾难使细胞对ATR抑制剂更加敏感

Siobhan O'Brien ,Tajinder Ubhi ,Lucie Wolf ,Krishna Gandhi ,Sichun Lin ,Naz Chaudary ,Neesha C Dhani ,Michael Milosevic ,Grant W Brown ,Stephane Angers

Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma

在一项随机、双盲、安慰剂对照的II期临床试验中,采用PRO-CTCAE量表对铂类耐药或难治性上皮性卵巢癌患者的耐受性进行自我报告,比较吉西他滨联合阿达沃塞替或安慰剂的疗效。

Madariaga, Ainhoa; Mitchell, Sandra A; Pittman, Tyler; Wang, Lisa; Bowering, Valerie; Kavak, Nisan; Quintos, Judy; Chang, Karen; Ramsahai, Janelle; Karakasis, Katherine; Welch, Stephen A; Dhani, Neesha C; Lheureux, Stephanie; Oza, Amit M

Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas

胰腺导管腺癌切除标本缺氧情况的数字定量组织图像分析

Siddiqui, Iram; Bilkey, Jade; McKee, Trevor D; Serra, Stefano; Pintilie, Melania; Do, Trevor; Xu, Jing; Tsao, Ming-Sound; Gallinger, Steve; Hill, Richard P; Hedley, David W; Dhani, Neesha C

Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

重新利用伊曲康唑和羟氯喹来靶向上皮性卵巢癌的溶酶体稳态

Stefano Marastoni #, Ainhoa Madariaga #, Aleksandra Pesic, Sree Narayanan Nair, Zhu Juan Li, Zvi Shalev, Troy Ketela, Ilaria Colombo, Victoria Mandilaras, Michael Cabanero, Jeff P Bruce, Xuan Li, Swati Garg, Lisa Wang, Eric X Chen, Sarbjot Gill, Neesha C Dhani, Wenjiang Zhang, Melania Pintilie, Vale

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

阿达沃塞替联合吉西他滨治疗铂耐药或铂难治性复发性卵巢癌:一项双盲、随机、安慰剂对照的II期试验

Lheureux, Stephanie; Cristea, Mihaela C; Bruce, Jeffrey P; Garg, Swati; Cabanero, Michael; Mantia-Smaldone, Gina; Olawaiye, Alexander B; Ellard, Susan L; Weberpals, Johanne I; Wahner Hendrickson, Andrea E; Fleming, Gini F; Welch, Stephen; Dhani, Neesha C; Stockley, Tracy; Rath, Prisni; Karakasis, Katherine; Jones, Gemma N; Jenkins, Suzanne; Rodriguez-Canales, Jaime; Tracy, Michael; Tan, Qian; Bowering, Valerie; Udagani, Smitha; Wang, Lisa; Kunos, Charles A; Chen, Eric; Pugh, Trevor J; Oza, Amit M